SPLENIC MARGINAL ZONE LYMPHOMA
Clinical trials for SPLENIC MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SPLENIC MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for SPLENIC MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for lymphoma patients: experimental drug epcoritamab enters phase 2 trial
Disease control Recruiting nowThis study tests whether the investigational drug epcoritamab can help people with newly diagnosed marginal zone lymphoma, a slow-growing blood cancer. About 25 adults will receive the drug and be monitored for complete remission after 12 cycles. The goal is to see if this treatm…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: Izidore Lossos, MD • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Scientists watch and learn: no treatment, just tracking blood cancers over time
Knowledge-focused Recruiting nowThis study follows up to 1,000 adults with certain slow-growing blood cancers (CLL, SLL, LPL, WM) to track how the diseases change over time. Participants have regular check-ups and blood draws every 6 to 24 months, and may also have optional biopsies or scans for research. No tr…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC